TM
MRNA icon

Triatomic Management’s Moderna MRNA Stock Holding History

Triatomic Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,250
Closed -$623K – 3
2024
Q2 		$623K Buy
+5,250
New +$664K 18.39% 3
2023
Q4 		– Sell
-5,250
Closed -$542K – 50
2023
Q3 		$542K Hold
5,250
– – 0.37% 37
2023
Q2 		$638K Buy
5,250
+850
+19% +$113K 0.65% 29
2023
Q1 		$676K Sell
4,400
-1,000
-19% -$165K 0.45% 35
2022
Q4 		$970K Hold
5,400
– – 0.82% 19
2022
Q3 		$639K Hold
5,400
– – 0.37% 31
2022
Q2 		$771K Hold
5,400
– – 0.71% 27
2022
Q1 		$930K Buy
+5,400
New +$909K 0.76% 27

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Triatomic Management's MRNA Position: Q3 2024 in Review

Triatomic Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 5,250 shares — an estimated $623K sold.

Triatomic Management first reported a position in MRNA in Q1 2022 and held it in 8 quarters. The position peaked at $970K in Q4 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Triatomic Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Triatomic Management sold 5,250 Moderna shares in Q3 2024, an estimated $623K.
  • Triatomic Management first reported a position in Moderna in Q1 2022 and held it in 8 quarters.
  • Triatomic Management's Moderna position peaked at $970K in Q4 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Triatomic Management's 13F filing for Q3 2024.